Skip to content
Blackberry Empire – Lifestyle
Author:
Sparrow Pharmaceuticals
Sparrow Pharmaceuticals Announces Interim CAPTAIN-T2D Data Validating High Prevalence of Elevated Cortisol in Difficult-to-Control Type 2 Diabetes
June 15, 2026
Sparrow Pharmaceuticals Announces Phase 2a Data Showing Cardiometabolic Benefits of Clofutriben in Adults with Type 2 Diabetes
June 8, 2026
Sparrow Pharmaceuticals Announces Acceptance of Late-Breaking Presentation of Interim Part 1 Results from CAPTAIN-T2D at the Endocrine Society (ENDO) 2026 Annual Meeting
June 3, 2026
Sparrow Pharmaceuticals to Present Phase 2a Results for Clofutriben in Type 2 Diabetes at the 2026 American Diabetes Association (ADA) Scientific Session
May 29, 2026